Diagnostic Needle Biopsies in Renal Masses: Patient and Physician Perspectives

Golan, Shay; Lotan, Paz; Tapiero, Shlomi; Baniel, Jack; Nadu, Andrei; Yossepowitch, Ofer

doi:10.1016/j.euf.2016.11.003

Cited by 6 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Facilitators: Eleven papers described predictive tools to support decision-making 12,13,15,17,20,22,27,33,35,44,48 . The RENAL nephrectomy score was used to help overcome selection bias 31 , assist surgeons in preoperative decision-making 48 and correlate with tumour histology and grade 35,44 .…”

Section: Predictive Toolsmentioning

confidence: 99%

“…Facilitators or barriers: Four papers suggested education status, socioeconomic status (SES), family history of cancer were all reported as facilitators or barriers to a patients' treatment decision-making 13,22,30,36 . One study reported that having an academic degree might be a facilitator in treatment decision-making 22 .…”

Section: Patient Related Criteriamentioning

confidence: 99%

“…Barriers: Cancer anxiety, related to personal as well as family history or the fear of missing a tumour, was reported as a strong barrier to active surveillance in the context of repeating biopsies 22,30 .…”

Section: Patient Related Criteriamentioning

confidence: 99%

“…The confidence in the management option of HCPs was also reported as a barrier. Golan et al reported that 40% of their participating urologists totally opposed a kidney mass biopsy 22 . 50% of urologists in a study by Barwari et al indicated that small kidney masses were the least important reason to perform a biopsy and 73% of the urologists very rarely or never recommended kidney mass biopsy for treatment decision-making 49 .…”

Section: Physician-related Criteriamentioning

confidence: 99%

See 3 more Smart Citations

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

et al. 2021

View full text Add to dashboard Cite

Introduction: With a growing number of treatment options for localised kidney cancer, patients and health care professionals have both the opportunity and the burden of selecting the most suitable management option. This mixed method systematic review aims to understand the barriers and facilitators of the treatment decision-making process in localised kidney cancer. Methods: We searched PubMed, Embase, and Cochrane Central databases between 1st of January 2004 and 23rd of April 2020 using the JBI Manual for Evidence Synthesis and the Preferred Reporting Items for Systematic Review and Meta-analysis statement. We identified 553 unique citations, of these 511 were excluded resulting in 42 articles included for synthesis. The Purpose, Respondents, Explanation, Findings and Significance and the Strengthening the Reporting of Observational Studies in Epidemiology checklist were applied. Results: The key themes describing barriers and facilitators to treatment decisionmaking were identified and categorised into three domains: (1) kidney cancer specific characteristics; (2) decision-maker related criteria; and (3) contextual factors.The main facilitators identified within these domains were: size at diagnosis, age, comorbidities, BMI, gender, nephrometry scoring systems, biopsy, socio-economic status, family history of cancer, year of diagnosis, geographic region and practice pattern. The key barriers were race, gender, patient anxiety, low confidence in diagnostic and treatment options, cost of procedure and practice patterns.

show abstract

Section: Predictive Toolsmentioning

confidence: 99%

Section: Patient Related Criteriamentioning

confidence: 99%

Section: Patient Related Criteriamentioning

confidence: 99%

Section: Physician-related Criteriamentioning

confidence: 99%

See 2 more Smart Citations

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…242 Similar techniques can be used to enhance adequacy for renal mass biopsies (kidney tumors) 243 but a significant inadequacy rate remains. 244 To enhance diagnostic adequacy and decrease clinical complications, specialized imaging, including optical coherence tomography 245,246 and Raman spectroscopy 247 performed through an image-guided needle, is an emerging alternative approach to renal mass biopsy. Small kidney masses less than 4 cm in diameter present special diagnostic and clinical management challenges, addressable by needle biopsy.…”

Section: Kidneymentioning

confidence: 99%

Needle Biopsy Adequacy in the Era of Precision Medicine and Value-Based Health Care

Pritzker

Nieminen

2019

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Needle biopsy of diseased tissue is an essential diagnostic tool that is becoming even more important as precision medicine develops. However, the capability of this modality to efficiently provide samples adequate for diagnostic and prognostic analysis remains quite limited relative to current diagnostic needs. For physicians and patients, inadequate biopsy frequently leads to diagnostic delay, procedure duplication, or insufficient information about tumor biology leading to delay in treatment; for health systems, this results in substantial incremental costs and inefficient use of scarce specialized diagnostic resources. Objective.— To review current needle biopsy technology, devices, and practice with a perspective to identify current limitations and opportunities for improvement in the context of advancing precision medicine. Data Sources.— PubMed searches of fine-needle aspiration and core needle biopsy devices and similar technologies were made generally, by tissue site, and by adequacy as well as by health economics of these technologies. Conclusions.— Needle biopsy adequacy can be improved by recognizing the importance of this diagnostic tool by promoting common criteria for needle biopsy adequacy; by optimizing needle biopsy procedural technique, technologies, clinical practice, professional education, and quality assurance; and by bundling biopsy procedure costs with downstream diagnostic modalities to provide better accountability and incentives to improve the diagnostic process.

show abstract

New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage

et al. 2018

View full text Add to dashboard Cite

Diagnostic Needle Biopsies in Renal Masses: Patient and Physician Perspectives

Cited by 6 publications

References 12 publications

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

Needle Biopsy Adequacy in the Era of Precision Medicine and Value-Based Health Care

New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage

Contact Info

Product

Resources

About